Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 17/20 | 0.55 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.46 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22420294 | 0.86 | HIF1A (0.46) | HIF1AEPAS1HSP90AA1EP300 | |
| SCHEMBL22420303 | 0.82 | HIF1A (0.46) | HIF1AEPAS1COXFA4 | |
| SCHEMBL5304916 | 0.81 | HIF1A (0.46) | HIF1AEPAS1 | |
| SCHEMBL16694229 | 0.80 | HIF1A (0.67) | HIF1AEPAS1HSP90AA1COXFA4 | |
| SCHEMBL16694230 | 0.80 | HIF1A (0.67) | HIF1AEPAS1HSP90AA1COXFA4 | |
| SCHEMBL16694313 | 0.80 | HIF1A (0.67) | HIF1AEPAS1HSP90AA1COXFA4 | |
| SCHEMBL16865542 | 0.80 | HIF1A (0.42) | HIF1AEPAS1COXFA4 | |
| SCHEMBL22420260 | 0.80 | HIF1A (0.50) | HIF1AEPAS1HSP90AA1EP300 | |
| SCHEMBL2560362 | 0.79 | HIF1A (0.60) | HIF1AEPAS1HSP90AA1EP300 | |
| SCHEMBL16694172 | 0.77 | COXFA4 (0.59) | HIF1AEPAS1HSP90AA1COXFA4EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772858-B2 | Benzhydrol derivatives for the management of conditions related to hypoxia inducible factors | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| EP-2871187-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2017-09-20 | — | — | EP | disclosed |
| EP-2871187-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2017-09-20 | — | — | EP | disclosed |
| US-9745280-B2 | Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | SNU R&DB FOUNDATION (KR) | 2017-08-29 | — | — | US | disclosed |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2016-11-24 | — | — | US | disclosed |
| US-20150183797-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2015-07-02 | — | — | US | disclosed |
| US-20150183797-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2015-07-02 | — | — | US | disclosed |
| EP-2871187-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB Foundation (KR) | 2015-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183797-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HSP90AB1, HSP90AA1, HIF1AN | HIF1A 5/4885EPAS1 55/4885HSP90AA1 2/4885 |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HSP90AB1, HSP90AA1, HSP90AB2P | HIF1A 6/4885EPAS1 72/4885HSP90AA1 2/4885 |
| US-10772858-B2 | Benzhydrol derivatives for the management of conditions related to hypoxia inducible factors | HIF1A, HIF1AN, EGLN2 | HIF1A 1/4885EPAS1 26/4885HSP90AA1 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.